GILD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the provided data, Gilead Sciences, Inc (GILD) does not currently present a strong buy opportunity for a beginner investor with a long-term strategy. The technical indicators are bearish, options sentiment is neutral, and there is no strong positive catalyst to justify immediate investment. Additionally, recent congress trading data indicates caution, and there is no AI Stock Picker or SwingMax signal to support a buy decision.
The technical indicators for GILD are bearish. The MACD is negative and expanding downward, the RSI is neutral at 37.441, and the moving averages show a bearish alignment (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 126.231, with key support at 122.308 and resistance at 130.154.
Analysts have upgraded the stock with higher price targets, citing growth potential in Yeztugo, Trodelvy, and HIV treatments.
The stock has experienced a pullback from all-time highs, and its P/E multiple is now in line with peers, reducing its valuation advantage. Congress trading data shows a recent sale transaction, indicating caution. Additionally, technical indicators are bearish, and there is no immediate positive momentum.
Financial data is unavailable for analysis. However, analysts have noted strong Q1 performance with top- and bottom-line beats and raised FY26 revenue guidance driven by HIV treatment strength.
Analyst sentiment is generally positive, with multiple upgrades and raised price targets. Maxim upgraded the stock to Buy with a $165 target, and Truist raised its target to $157. However, RBC Capital remains more conservative with a Sector Perform rating and a $122 target.
